JP2018502838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502838A5 JP2018502838A5 JP2017530094A JP2017530094A JP2018502838A5 JP 2018502838 A5 JP2018502838 A5 JP 2018502838A5 JP 2017530094 A JP2017530094 A JP 2017530094A JP 2017530094 A JP2017530094 A JP 2017530094A JP 2018502838 A5 JP2018502838 A5 JP 2018502838A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- camkk1
- tissue
- organ
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 30
- 102100019607 CAMKK1 Human genes 0.000 claims 19
- 101710003269 CAMKK1 Proteins 0.000 claims 19
- 210000000056 organs Anatomy 0.000 claims 13
- 210000001519 tissues Anatomy 0.000 claims 13
- 210000004027 cells Anatomy 0.000 claims 7
- 210000000130 stem cell Anatomy 0.000 claims 6
- 230000000302 ischemic Effects 0.000 claims 5
- 101700054205 DAB2 Proteins 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 206010018651 Graft versus host disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 210000002216 Heart Anatomy 0.000 claims 2
- 206010022114 Injury Diseases 0.000 claims 2
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003636 conditioned culture media Substances 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001172 regenerating Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000003612 virological Effects 0.000 claims 2
- 206010000891 Acute myocardial infarction Diseases 0.000 claims 1
- 210000000577 Adipose Tissue Anatomy 0.000 claims 1
- 210000001367 Arteries Anatomy 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 206010007709 Cartilage disease Diseases 0.000 claims 1
- 206010061762 Chondropathy Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010070976 Craniocerebral injury Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 210000004322 M2 macrophage Anatomy 0.000 claims 1
- 229920001922 Mir-145 Polymers 0.000 claims 1
- 210000001616 Monocytes Anatomy 0.000 claims 1
- 210000004165 Myocardium Anatomy 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims 1
- 210000003954 Umbilical Cord Anatomy 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004271 bone marrow stromal cells Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000003511 endothelial Effects 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000009673 liver disease Diseases 0.000 claims 1
- 230000002175 menstrual Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001537 neural Effects 0.000 claims 1
- 230000000399 orthopedic Effects 0.000 claims 1
- 230000003169 placental Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 200000000019 wound Diseases 0.000 claims 1
Claims (23)
- 患者の臓器または組織における虚血または炎症状態を処置するための組成物であって、該臓器または組織におけるCAMKK1のレベルの増加を誘導する物質を含む、組成物。
- 前記臓器または組織が、心臓、肝臓、腎臓、脳、脊椎、肺、小腸、大腸、動脈、関節、軟骨、皮膚、またはそれらのあらゆる組合せである、請求項1に記載の組成物。
- 前記臓器または組織が、前記心臓または心筋である、請求項2に記載の組成物。
- 前記臓器または組織におけるCAMKK1のレベルの増加が、CAMKK1タンパク質を前記臓器または組織に投与することによって達成される、請求項1に記載の組成物。
- 前記臓器または組織におけるCAMKK1のレベルの増加が、CAMKK1をコードする核酸を含むベクターを前記臓器または組織に投与することによって達成される、請求項1に記載の組成物。
- 前記ベクターが、プラスミドまたはウイルスベクターである、請求項5に記載の組成物。
- 前記臓器または組織におけるCAMKK1のレベルの増加が、増加したレベルのCAMKK1を生産するように改変された細胞を投与することによって達成される、請求項1に記載の組成物。
- 前記臓器または組織におけるCAMKK1のレベルの増加が、前記CAMKK1のレベルの増加がもたらされるように改変された細胞の培養物からの馴化培地を投与することによって達成される、請求項1に記載の組成物。
- 前記細胞が、CAMKK1をコードする核酸を含むベクターで改変された、請求項7または8に記載の組成物。
- 前記ベクターが、プラスミドまたはウイルスベクターを含む、請求項9に記載の組成物。
- 前記細胞が、CAMKK1の発現を誘導する薬剤で改変された、請求項7または8に記載の組成物。
- 前記薬剤が、TGF−β、miR145、Dab2阻害剤、またはそれらのあらゆる組合せである、請求項11に記載の組成物。
- 前記Dab2阻害剤が、Dab2のsiRNAである、請求項12に記載の組成物。
- 前記CAMKK1が、構成的に活性なCAMKK1である、請求項1に記載の組成物。
- 前記構成的に活性なCAMKK1が、CAMKK1 1−413トランケート型を含む、請求項14に記載の組成物。
- 前記構成的に活性なCAMKK1が、T108A突然変異CAMKK1、S459A突然変異CAMKK1、またはT108A/S459A突然変異CAMKK1を含む、請求項14に記載の組成物。
- 前記タンパク質、ベクター、細胞、または馴化培地が、全身投与されるか、虚血もしくは炎症を起こした組織に直接投与されるか、または虚血もしくは炎症を起こした組織の周辺に投与される、請求項4、5、7、または8のいずれか一項に記載の組成物。
- 前記細胞が、間葉系幹細胞である、請求項7または8に記載の組成物。
- 前記虚血または炎症状態が、急性心筋梗塞、心不全、末梢動脈疾患、卒中、肝疾患、虚血性腎疾患、多発性硬化症、外傷性脳損傷、脊髄の損傷、移植片対宿主疾患(GVHD)、糖尿病、慢性閉塞性肺疾患(COPD)、関節リウマチ、固形臓器移植による傷害、整形外科の傷害、軟骨障害、創傷、またはそれらのあらゆる組合せである、請求項1に記載の組成物。
- 1つまたは複数の追加の再生療法を投与することをさらに含む、請求項1に記載の組成物。
- 前記1つまたは複数の再生療法が、骨髄に由来する間葉系幹細胞、脂肪組織、胎盤組織、臍帯、ホウォートンゼリー、月経血、幹細胞、M2マクロファージ、単球、またはそれらのあらゆる組合せである、請求項20に記載の組成物。
- 前記幹細胞が、神経前駆細胞、内皮前駆細胞、臓器特異的な内因性幹細胞、またはそれらのあらゆる組合せである、請求項21に記載の組成物。
- 前記臓器特異的な内因性幹細胞が、心臓のckit+細胞である、請求項22に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021032502A JP2021098717A (ja) | 2014-12-01 | 2021-03-02 | 新規の再生治療剤としてのcamkk1 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086026P | 2014-12-01 | 2014-12-01 | |
US62/086,026 | 2014-12-01 | ||
PCT/US2015/063118 WO2016089826A1 (en) | 2014-12-01 | 2015-12-01 | Camkk1 as a novel regenerative therapeutic |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021032502A Division JP2021098717A (ja) | 2014-12-01 | 2021-03-02 | 新規の再生治療剤としてのcamkk1 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018502838A JP2018502838A (ja) | 2018-02-01 |
JP2018502838A5 true JP2018502838A5 (ja) | 2019-01-17 |
JP6893873B2 JP6893873B2 (ja) | 2021-06-23 |
Family
ID=56092307
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017530094A Active JP6893873B2 (ja) | 2014-12-01 | 2015-12-01 | 新規の再生治療剤としてのcamkk1 |
JP2021032502A Pending JP2021098717A (ja) | 2014-12-01 | 2021-03-02 | 新規の再生治療剤としてのcamkk1 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021032502A Pending JP2021098717A (ja) | 2014-12-01 | 2021-03-02 | 新規の再生治療剤としてのcamkk1 |
Country Status (13)
Country | Link |
---|---|
US (2) | US11273208B2 (ja) |
EP (2) | EP3227441B1 (ja) |
JP (2) | JP6893873B2 (ja) |
KR (3) | KR102236843B1 (ja) |
AU (1) | AU2015355188B2 (ja) |
BR (1) | BR112017011490A2 (ja) |
CA (1) | CA3007055C (ja) |
CL (1) | CL2017001390A1 (ja) |
CR (1) | CR20170301A (ja) |
IL (2) | IL252612B (ja) |
RU (1) | RU2017122817A (ja) |
UA (1) | UA124450C2 (ja) |
WO (1) | WO2016089826A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017011490A2 (pt) * | 2014-12-01 | 2018-02-27 | Northeast Ohio Medical Univ | método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente |
JP2021521193A (ja) * | 2018-04-18 | 2021-08-26 | スンマ ヘルスSumma Health | 虚血および心筋症の処置のための組成物および方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6426206B1 (en) | 2000-11-13 | 2002-07-30 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
WO2002072115A2 (en) | 2001-03-09 | 2002-09-19 | Board Of Regents, The University Of Texas System | Vectors, compositions and methods for treating a vascular disorder |
US7776564B2 (en) | 2004-04-30 | 2010-08-17 | Five Prime Therapeutics, Inc. | Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
US7764995B2 (en) * | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
WO2006015127A2 (en) * | 2004-07-30 | 2006-02-09 | Mayo Foundation For Medical Education And Research | Treating cardiovascular tissue |
CA2581237C (en) | 2004-09-24 | 2018-11-06 | Angioblast Systems, Inc. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc) |
US20090246179A1 (en) | 2008-02-11 | 2009-10-01 | The Cleveland Clinic Foundation | Method of treating myocardial injury |
EP2687219A1 (en) * | 2012-07-18 | 2014-01-22 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions |
SG11201600219TA (en) * | 2013-08-29 | 2016-02-26 | Stempeutics Res Pvt Ltd | Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof |
BR112017011490A2 (pt) * | 2014-12-01 | 2018-02-27 | Northeast Ohio Medical Univ | método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente |
US20180021378A1 (en) | 2014-12-31 | 2018-01-25 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
-
2015
- 2015-12-01 BR BR112017011490A patent/BR112017011490A2/pt active Search and Examination
- 2015-12-01 CR CR20170301A patent/CR20170301A/es unknown
- 2015-12-01 UA UAA201706834A patent/UA124450C2/uk unknown
- 2015-12-01 AU AU2015355188A patent/AU2015355188B2/en active Active
- 2015-12-01 KR KR1020177018031A patent/KR102236843B1/ko active IP Right Grant
- 2015-12-01 WO PCT/US2015/063118 patent/WO2016089826A1/en active Application Filing
- 2015-12-01 CA CA3007055A patent/CA3007055C/en active Active
- 2015-12-01 KR KR1020227037365A patent/KR102610068B1/ko active IP Right Grant
- 2015-12-01 JP JP2017530094A patent/JP6893873B2/ja active Active
- 2015-12-01 KR KR1020217001921A patent/KR102460983B1/ko active IP Right Grant
- 2015-12-01 EP EP15864736.2A patent/EP3227441B1/en active Active
- 2015-12-01 RU RU2017122817A patent/RU2017122817A/ru not_active Application Discontinuation
- 2015-12-01 EP EP21182570.8A patent/EP3940068A1/en active Pending
-
2017
- 2017-05-31 CL CL2017001390A patent/CL2017001390A1/es unknown
- 2017-05-31 US US15/610,540 patent/US11273208B2/en active Active
- 2017-06-01 IL IL252612A patent/IL252612B/en unknown
-
2021
- 2021-03-02 JP JP2021032502A patent/JP2021098717A/ja active Pending
- 2021-06-27 IL IL284408A patent/IL284408B/en unknown
-
2022
- 2022-02-08 US US17/667,375 patent/US20220233653A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bartolucci et al. | Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]) | |
Tarui et al. | Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial | |
Schächinger et al. | Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial | |
Naderi‐Meshkin et al. | Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy | |
Takahashi | Role of the SDF-1/CXCR4 system in myocardial infarction | |
Cabrera-Benitez et al. | Mechanical ventilation–associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome | |
Guo et al. | Cell sheet formation enhances the therapeutic effects of human umbilical cord mesenchymal stem cells on myocardial infarction as a bioactive material | |
ES2401608T3 (es) | Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes | |
Cabrera-Fuentes et al. | RNase1 as a potential mediator of remote ischaemic preconditioning for cardioprotection | |
Hu et al. | Islet-1 mesenchymal stem cells-derived exosome-incorporated angiogenin-1 hydrogel for enhanced acute myocardial infarction therapy | |
Bagno et al. | Sustained IGF-1 secretion by adipose-derived stem cells improves infarcted heart function | |
JP2016515533A5 (ja) | ||
JP2014088432A5 (ja) | ||
Grauss et al. | Mesenchymal stem cells from ischemic heart disease patients improve left ventricular function after acute myocardial infarction | |
Faris et al. | Therapeutic potential of endothelial colony-forming cells in ischemic disease: strategies to improve their regenerative efficacy | |
JP2009545310A5 (ja) | ||
Zhao et al. | Mesenchymal stem cell biodistribution, migration, and homing in vivo | |
Tang et al. | VEGF-A promotes cardiac stem cell engraftment and myocardial repair in the infarcted heart | |
JP2012500199A5 (ja) | ||
Griffin et al. | Genetically modified mesenchymal stem cells and their clinical potential in acute cardiovascular disease | |
JP2018502838A5 (ja) | ||
ES2885080T3 (es) | Composición inyectable que comprende fibroblastos para su utilización en el tratamiento de cardiopatías | |
Zhong et al. | The current status and future of cardiac stem/progenitor cell therapy for congenital heart defects from diabetic pregnancy | |
Pagano et al. | On the road to regeneration:“tools” and “routes” towards efficient cardiac cell therapy for ischemic cardiomyopathy | |
Kloc et al. | Reciprocal interactions between mesenchymal stem cells and macrophages |